Table 1.
Cumulative incidence of recurrence in bone at any time in patients with 16q23 CNA*
| Variable | Univariate (n = 313) | Multivariable (n = 313) | ||
|---|---|---|---|---|
| HR (95% CI) |
P | HR (95% CI) |
P | |
| Menopausal status | .597 | - | ||
| Premenopausal | 1.00 (referent) | - | ||
| Postmenopausal | 0.81 (0.37 to 1.74) |
- - |
||
| Tumor size, mm | .12 | .299 | ||
| ≤20 | 1.00 (referent) | 1.00 (referent) | ||
| 21–50 | 1.86 (0.87 to 3.93) |
1.56 (0.63 to 3.81) |
||
| >50 | 1.73 (0.60 to 5.01) |
0.56 (0.12 to 2.57) |
||
| Tumor grade | .174 | .160 | ||
| I | 1.00 (referent) | 1.00 (referent) | ||
| II | 0.87 (0.41 1.83) |
2.75 (0.32 to 23.33) |
||
| III | 1.58 (0.75 to 3.33) |
1.12 (0.12 to 10.27) |
||
| Lymph nodes | .120 | .255 | ||
| None | 1.00 (referent) | 1.00 (referent) | ||
| 1–3 | 0.94 (0.41 to 2.14) |
1.20 (0.46 to 3.11) |
||
| 4–9 | 1.27 (0.38 to 4.24) |
1.79 (0.33 to 9.54) |
||
| >9 | 3.39 (1.17 to 9.81) |
4.57 (1.16 to 18.01) |
||
| Hormonal receptor status | .414 | - | ||
| Negative | 1.00 (referent) | - | ||
| Positive | 0.71 (0.32 to 1.57) |
- - |
||
| HER2 status | .580 | - | ||
| Negative | 1.00 (referent) | - | ||
| Positive | 1.30 (0.52 to 3.22) |
- - |
||
| Proliferation (Ki-67) | .010 | .263 | ||
| Low proliferation (<15%) | 1.00 (referent) | 1.00 (referent) | ||
| High proliferation (≥15%) | 2.81 (1.37 to 6.34) |
1.65 (0.68 to 3.98) |
||
| 16q23 (FISH CNA) | 1x10-11 | 3x10-10 | ||
| Below 1.5 | 1.00 (referent) | 1.00 (referent) | ||
| Equal or More 1.5 | 14.5 (6.4 to 32.9) |
18.02 (6.69 to 48.53) |
||
* Measured from date of primary tumor surgical resection. Analyzed by Cox cause-specific hazards model with competing events (death before recurrence in bone). The risk of the competing event is reported in Supplementary Table 2 (available online). CI = confidence interval; CNA = copy number aberration; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio.